Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2007-11-09
- Target Recruit Count
- 94
- Registration Number
- NCT00556127
- Locations
- 🇮🇹
Centro Trapianti Midollo Osseo, P.O. Businco, Cagliari, Italy
🇮🇹Ospedale S. Gerardo, Monza, Italy
🇮🇹Osp. maggiore della Carità, Novara, Italy
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-01-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT00526305
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸H.U. Virgen del Rocio, Sevilla, Spain
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-08-07
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 52
- Registration Number
- NCT00512252
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 14
- Registration Number
- NCT00510887
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-02-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 399
- Registration Number
- NCT00499018
- Locations
- 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00477087
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 22
- Registration Number
- NCT00452387
- Locations
- 🇺🇸
Hematology Oncology Centers of the Northern Rockies, PC, Billings, Montana, United States
🇺🇸The West Clinic, Memphis, Tennessee, United States
🇺🇸Lancaster Cancer Center, Lancaster, Pennsylvania, United States
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00447473
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Taxotere Prostate Cancer New Indication Registration Trial in China
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 228
- Registration Number
- NCT00436839
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 755
- Registration Number
- NCT00417079
- Locations
- 🇭🇺
Sanofi-Aventis Hungaria, Budapest, Hungary
🇫🇮sanofi-aventis Finland, Helsinki, Finland
🇮🇳sanofi-aventis India, Mumbai, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.